Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS) ; volume:21 ; number:1 ; day:21 ; month:12 ; year:2024 ; pages:1-13 ; date:12.2024
AIDS research and therapy ; 21, Heft 1 (21.12.2024), 1-13, 12.2024
- Creator
-
Yan, Lei
Henegar, Cassidy E.
Marconi, Vincent C.
Gordon, Kirsha S.
Hicks, Charles
Vannappagari, Vani
Justice, Amy C.
Aslan, Mihaela
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12981-024-00681-w
- URN
-
urn:nbn:de:101:1-2503022115233.395123999357
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yan, Lei
- Henegar, Cassidy E.
- Marconi, Vincent C.
- Gordon, Kirsha S.
- Hicks, Charles
- Vannappagari, Vani
- Justice, Amy C.
- Aslan, Mihaela
- SpringerLink (Online service)
Other Objects (12)
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
CD56 expression predicts response to Daratumumab-based regimens
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
Food-regimens for diabetes mellitus
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
Emerging agents and regimens for AML
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
CD56 expression predicts response to Daratumumab-based regimens
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
Food-regimens for diabetes mellitus
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
Emerging agents and regimens for AML
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
CD56 expression predicts response to Daratumumab-based regimens
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
Food-regimens for diabetes mellitus
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
Emerging agents and regimens for AML
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV